1. Taking a Closer Look at Recurrent/Metastatic SCCHN

2. Introduction

3. Current Treatment Guidelines for Recurrent/Metastatic SCCHN

4. EXTREME Study Design

5. Platinum-Based Chemotherapy Plus Cetuximab: EXTREME Trial

6. EXTREME Trial: Hazard Ratios for Death

7. EXTREME Trial: Hazard Ratios for Disease Progression

8. EXTREME Trial: Safety Profile

9. Limitations of the EXTREME Regimen

10. KEYNOTE-048 Study Design

11. OS: P vs E, in the CPS ≥ 1% and CPS ≥ 20% Populations

12. PFS: P vs E, in the CPS ≥ 1% and CPS ≥ 20% Populations

13. Response Summary: P vs E (Confirmed Responses)

14. KEYNOTE-048 Safety Results, P vs E, Total Population

15. OS and PFS: P + CT vs E, Total Population

16. Response Summary, P + CT vs E, Total Population (Confirmed Responses)

17. KEYNOTE-048 Safety Results, P + CT vs E, Total Population

18. How Might These Data Influence the Current Treatment Algorithm?

19. Limitations of KEYNOTE-048

20. PD-L1 Positivity of ICs and TCs Among Different Primary Tumor Site

21. How Might These Data Influence the Current Treatment Algorithm? (cont)

22. PD-L1 Data From the IMPASSION130 Study (TNBC)

23. Potential Implications of KEYNOTE-048 on Choice of Second-Line Therapy

24. Some Promising Immunotherapies Agents Under Development in SCCHN

25. SD-101 + Pembrolizumab in Anti-PD-1/PD-L1 Treatment-Naive R/M SCCHN (SYNERGY-001)

26. M7824 (MSB0011359C) in Advanced SCCHN: Results From a Phase 1 Cohort

27. Durvalumab + Danvatirsen or CX2i: Phase 1b/2 (SCORES)

28. Monalizumab + Cetuximab: Phase 2 Study

29. Conclusions

30. Abbreviations

31. Abbreviations (cont)